Published in Lancet on May 19, 2007
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) | NCT00092534
Evaluation of Long Term Immunity Following HPV Vaccination | NCT02276521
Acceptance of Human Papillomavirus Vaccination in Postpartum Women (HPV Acceptance) | NCT00730704
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ (2011) 3.90
Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ (2007) 3.77
Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (2008) 3.08
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol (2009) 2.46
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine (2008) 2.13
A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med (2010) 1.81
Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med (2010) 1.63
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics (2010) 1.57
Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010. Cancer (2012) 1.41
Integrating clinical, community, and policy perspectives on human papillomavirus vaccination. Annu Rev Public Health (2010) 1.39
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr (2010) 1.35
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35
Nitric oxide and cancer: a review. World J Surg Oncol (2013) 1.22
Cervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection. BMC Infect Dis (2012) 1.13
Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol (2009) 1.03
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev (2010) 1.02
A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology (2009) 1.01
The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One (2013) 1.00
Prevalence of human papillomavirus genotypes in HIV-1-infected women in Seattle, USA and Nairobi, Kenya: results from the Women's HIV Interdisciplinary Network (WHIN). Int J Infect Dis (2010) 0.98
Prevention of HPV-related oral cancer: assessing dentists' readiness. Public Health (2014) 0.97
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma. Biomed Res Int (2014) 0.95
Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer (2013) 0.94
High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One (2013) 0.93
Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. Br J Cancer (2008) 0.92
Geospatial patterns of human papillomavirus vaccine uptake in Minnesota. BMJ Open (2015) 0.91
The implementation and acceptability of an HPV vaccination decision support system directed at both clinicians and families. AMIA Annu Symp Proc (2012) 0.90
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Effect of the decision-making process in the family on HPV vaccination rates among adolescents 9-17 years of age. Hum Vaccin Immunother (2014) 0.87
Interaction between Chronic Inflammation and Oral HPV Infection in the Etiology of Head and Neck Cancers. Int J Otolaryngol (2012) 0.87
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis (2012) 0.87
Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. Int J STD AIDS (2010) 0.86
Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine. Int J Womens Health (2010) 0.84
Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) (2014) 0.84
Financial incentives for increasing uptake of HPV vaccinations: a randomized controlled trial. Health Psychol (2014) 0.84
Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program. Am J Obstet Gynecol (2013) 0.83
A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines. BMC Public Health (2015) 0.83
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ (2007) 0.83
Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda. Int J STD AIDS (2008) 0.83
Lessons from Australia: human papillomavirus is not a major risk factor for esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2010) 0.82
Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status. BMC Infect Dis (2015) 0.82
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis (2016) 0.81
Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev (2012) 0.81
Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland. Virol J (2009) 0.81
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One (2014) 0.81
Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr Opin Virol (2011) 0.80
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study. Wien Klin Wochenschr (2013) 0.80
CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles. PLoS One (2010) 0.80
Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS One (2011) 0.80
Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One (2014) 0.80
Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009. Clin Ther (2010) 0.80
Human papillomavirus vaccine for children and adolescents. Paediatr Child Health (2007) 0.79
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79
Ethical considerations of universal vaccination against human papilloma virus. BMC Med Ethics (2014) 0.79
Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine. Clin Vaccine Immunol (2013) 0.79
Risk perceptions, sexual attitudes, and sexual behavior after HPV vaccination in 11-12 year-old girls. Vaccine (2015) 0.79
Barriers to HPV immunization among blacks and latinos: a qualitative analysis of caregivers, adolescents, and providers. BMC Public Health (2016) 0.77
The utility and management of vaginal cytology after treatment for endometrial cancer. Obstet Gynecol (2013) 0.77
"Knowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverage". BMC Public Health (2014) 0.77
HPV genotypes in paraffin sections of non-cervical squamous cell carcinoma in Qingdao of China. Oncol Lett (2013) 0.77
Rome Consensus Conference - statement; human papilloma virus diseases in males. BMC Public Health (2013) 0.77
Position paper--HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians. Eur J Pediatr (2010) 0.76
Kissing and hpv: honest popular visions, the human papilloma virus, and cancers. Curr Oncol (2014) 0.76
Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world? Ann Med Health Sci Res (2013) 0.76
Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PLoS One (2014) 0.75
Molecular genotyping of human papillomavirus l1 gene in low-risk and high-risk populations in Bangkok. Sex Transm Dis (2015) 0.75
Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). Hum Vaccin Immunother (2015) 0.75
HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee. Hum Vaccin Immunother (2015) 0.75
"Saving lives": Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria. Soc Sci Med (2016) 0.75
Warts (genital). BMJ Clin Evid (2010) 0.75
Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV. Infect Dis Obstet Gynecol (2014) 0.75
HPV vaccines: a controversial issue? Braz J Med Biol Res (2016) 0.75
Human papillomavirus-related gynecologic neoplasms: screening and prevention. Rev Obstet Gynecol (2008) 0.75
Awareness and acceptance of human papillomavirus vaccination among health sciences students in Malaysia. Virusdisease (2015) 0.75
Current issues facing the introduction of human papillomavirus vaccine in malaysia. Malays Fam Physician (2007) 0.75
An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clin Vaccine Immunol (2010) 0.75
Correlates of Human Papillomavirus Vaccine Completion Among Adolescent Girl Initiators. Clin Pediatr (Phila) (2015) 0.75
What do women with gynecologic cancer know about HPV and their individual disease? A pilot study. BMC Cancer (2014) 0.75
[Researcher of the month, October 2012]. Wien Klin Wochenschr (2012) 0.75
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc (2017) 0.75
Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial. Wien Klin Wochenschr (2008) 0.75
Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. Vaccine (2017) 0.75
Impact of HPV vaccination: health gains in the Italian female population. Popul Health Metr (2017) 0.75
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol (2008) 6.20
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol (2012) 6.05
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96
Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: a series of 50 cases from a tertiary teaching hospital. Acta Obstet Gynecol Scand (2012) 5.93
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Why did so many women develop cancer? N Z Med J (2010) 4.66
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ (2009) 4.31
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res (2012) 3.82
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55